Voyager Therapeutics (VYGR) EBT Margin (2015 - 2026)
Voyager Therapeutics (VYGR) reported EBT Margin of 1076.86% for Q1 2026, down 59820.0% on a YoY basis from N/an in Q1 2025, and down 503.85% sequentially from 178.33% in Q4 2025.
Voyager Therapeutics (VYGR) EBT Margin (2015 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 12 years of EBT Margin data on file, last reported at 1076.86% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 59820.0% year-over-year to 1076.86%; the trailing twelve-month figure through Mar 2026 stood at 318.94% (down 19353.0% YoY), and the FY2025 full-year result was 296.17%, down 21575.0% from the prior year.
- EBT Margin eased to 1076.86% in Q1 2026, from 178.33% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1523.23% in Q4 2022 to a low of 3239.97% in Q1 2022.
- A 5-year average of 498.58% and a median of 208.07% in 2025 frame the typical range for EBT Margin.
- Peak annual rise in EBT Margin reached 569317 bps in 2022, while the deepest fall reached 189616 bps in 2022.
- Tracing VYGR's EBT Margin over 5 years: stood at 1523.23% in 2022, then slumped by 96 bps to 63.5% in 2023, then plunged by 947 bps to 538.06% in 2024, then surged by 67 bps to 178.33% in 2025, then tumbled by 504 bps to 1076.86% in 2026.
- Business Quant data shows VYGR's EBT Margin at 1076.86% in Q1 2026, 178.33% in Q4 2025, and 208.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Voyager Therapeutics | 183.84 Mn | 42.36 Mn | - | -1,076.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,076.86% |
| Dec 31, 2025 | -178.33% |
| Sep 30, 2025 | -208.07% |
| Jun 30, 2025 | -641.67% |
| Mar 31, 2025 | -478.67% |
| Dec 31, 2024 | -538.06% |
| Sep 30, 2024 | -36.55% |
| Jun 30, 2024 | -34.20% |
| Mar 31, 2024 | -58.03% |
| Dec 31, 2023 | 63.50% |
| Sep 30, 2023 | -565.19% |
| Jun 30, 2023 | -452.02% |
| Mar 31, 2023 | 82.90% |
| Dec 31, 2022 | 1,523.23% |
| Sep 30, 2022 | 42.90% |
| Jun 30, 2022 | -2,680.76% |
| Mar 31, 2022 | -3,239.97% |
| Dec 31, 2021 | -362.88% |
| Sep 30, 2021 | -5,650.27% |
| Jun 30, 2021 | -3,147.68% |